T2 Biosystems

T2 Biosystems, Inc. engages in the development of a proprietary technology platform. It offers the T2 Magnetic Resonance technology, which enables detection of pathogens, biomarkers, and other abnormalities in a range of unpurified patient sample types. The firm's products include the T2Dx Instrument, the T2Candida Panel, the T2Bacteria Panel, the T2Resistance Panel, and the T2SARS-CoV-2 Panel. The company was founded by Michael J. Cima, Robert S. Langer Jr., Tyler Jacks, Lee Josephson, W. David Lee, and Ralph Weissleder on April 27, 2006 and is headquartered in Lexington, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

T2 Biosystems reports revenue growth, eyes FDA breakthroughs for expansion

T2 Biosystems demonstrated strong revenue growth and operational improvements in Q3 2024, driven by sepsis test panel sales and strategic partnerships.
While facing financial challenges and regulatory complexities, the company's focus on innovation and market expansion presents significant opportunities for future growth.
Overall, T2 Biosystems remains optimistic about its growth prospects, supported by advancements in its product pipeline and collaborations to combat healthcare challenges.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

T2 Biosystems, Inc. is a vitro diagnostics company, which engages in the development of detection of sepsis-causing pathogens. It offers T2Dx instrument, T2Bacteria, T2Candida, T2Biothreat panels, and T2MR technology. The company was founded by Michael J. Cima, Robert S. Langer Jr., Tyler Jacks, Lee Josephson, W. David Lee, and Ralph Weissleder on April 27, 2006 and is headquartered in Lexington, MA.

T2 Biosystems makes medical diagnostic testing equipment. The company reported a likely 60% in revenue in a preliminary third-quarter earnings report.

Why Shares of T2 Biosystems Are Falling Friday

T2 Biosystems, Inc. (NASDAQ:TTOO ) Preliminary Q3 2023 Earnings Call Transcript October 12, 2023 4:30 PM ET Company Participants Trip Taylor - IR John Sperzel - Chairman & CEO Conference Call Participants Kyle Mikson - Canaccord Ben Haynor - Alliance Global Partners Operator Greetings. Welcome to T2 Biosystems Preliminary Third Quarter 2023 Financial Results and Business Update Call.

T2 Biosystems, Inc. (TTOO) Preliminary Q3 2023 Earnings Call Transcript

Received FDA 510(k) clearance for the T2Biothreat Panel and significantly strengthened balance sheet Received FDA 510(k) clearance for the T2Biothreat Panel and significantly strengthened balance sheet

T2 Biosystems Announces Preliminary Third Quarter 2023 Financial Results and Business Updates

LEXINGTON, Mass., Oct. 12, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) to expand the number of pathogens detected on the FDA-cleared T2Bacteria® Panel to include the detection of Acinetobacter baumannii (A. baumannii).

T2 Biosystems Announces FDA 510(k) Submission to Expand the Pathogen Detection on its FDA-Cleared T2Bacteria Panel to Include Detection of Acinetobacter baumannii

Shares of T2 Biosystems (NASDAQ: TTOO ) are cratering lower today. This comes after the in vitro diagnostics company announced that its board of directors approved a 1-for-100 reverse stock split.

TTOO Stock Alert: T2 Biosystems Announces Reverse Stock Split

TTOO common stock expected to begin trading on a split-adjusted basis on October 13, 2023 TTOO common stock expected to begin trading on a split-adjusted basis on October 13, 2023

T2 Biosystems Announces Reverse Stock Split Effective Today

T2 Biosystems (NASDAQ: TTOO) stock price will be in the spotlight on Thursday as the company publishes its financial results. The shares jumped to a high of $0.3090, a few points above this month's low of $0.1500.

TTOO stock price: brace for T2 Biosystems volatility after earnings

Hub Cyber Security Ltd

Novo Integrated Sciences, Inc.

Penny stocks are highly popular among day and swing traders because of their low prices and volatility. Most of these stocks are usually bad long-term investments because of their unprofitability, especially in a high-interest rates environment.

Top 3 penny stocks to day trade: HUBC, TTOO, NVOS

Genius Group Ltd

Sirius XM Holdings Inc

If you're wondering what's going on in the stock market today, or trying to find the best penny stocks to buy now, understand that global tensions have heated up over the weekend in the Middle East. This followed an incursion by armed militants into Israeli territory.

Penny Stocks To Buy Now? 3 To Watch In The Stock Market Today

LEXINGTON, Mass., Oct. 06, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the rapid detection of sepsis-causing pathogens, announced today that it issued inducement awards to nine new employees.

T2 Biosystems Reports Granting of Inducement Award

T2 Biosystems (NASDAQ: TTOO ) announced today that it would report its preliminary quarterly earnings and provide business updates after the market closes on Oct. 12. In early trading, TTOO stock is jumping 20%.

Dear TTOO Stock Fans, Mark Your Calendars for Oct. 12

LEXINGTON, Mass., Oct. 05, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will report preliminary financial results for the third quarter 2023 and business updates after market close on Thursday, October 12, 2023. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.

T2 Biosystems to Report Preliminary Third Quarter 2023 Financial Results and Business Updates on October 12, 2023

Another day, another sale of T2 Biosystems (NASDAQ: TTOO ) for 10% owner CR Group (CRG). Since Sept.

TTOO Stock Alert: A Key Investor Just Dumped Another 13 Million Shares

Shares of T2 Biosystems (NASDAQ: TTOO ) are up by over 20% today on the heels of receiving U.S. Food and Drug Administration (FDA) 510(k) clearance for its T2Biothreat Panel. The panel is a direct-from-blood molecular diagnostic test that has the ability to simultaneously detect six biothreat pathogens.

The Cost to Borrow T2 (TTOO) Stock Is Up 130% in Just 10 Days

Shares of beleaguered biotechnology specialist T2 Biosystems (NASDAQ: TTOO ) continue their worrying descent despite the announcement of positive news. Most alarmingly, a major investor has been exiting out of TTTO stock in recent days.

CR Group Just Sold More Shares of T2 Biosystems (TTOO) Stock

T2 Biosystems (NASDAQ: TTOO) stock price sell-off continued as the company continued facing numerous headwinds. The shares dropped to a low of $0.1884 on Tuesday, the lowest level since August 2nd.

TTOO stock price outlook as big shareholder dumps shares

Among the small-cap stocks garnering attention today is T2 Biosystems (NASDAQ: TTOO ). Shares of TTOO stock are down more than 14% in afternoon trading on an announcement that a key investor is in selling mode.

CR Group Just Sold 10 Million Shares of T2 (TTOO) Stock

Shares of T2 Biosystems Inc. extended their losing streak to two days Wednesday despite the biotech clinching regulatory approval for a key diagnostic test.

T2 Biosystems' stock extends losing streak despite FDA approval for anthrax and plague diagnostic test

T2 Biosystems Inc., a Lexington, Mass.-based developer of diagnostics for rapid identification of dangerous pathogens, has reached a key regulatory milestone that could alter its near-term future, according to one analyst.

T2 Biosystems reaches regulatory milestone that could be a game changer, analyst says

T2 Biosystems (NASDAQ: TTOO ) stock can officially be added to an unfortunate list that includes fellow meme stocks Mullen Automotive (NASDAQ: MULN ) and Meta Materials (NASDAQ: MMAT ). What's the list?

TTOO Stock Alert: T2 Confirms FDA Clearance for Biothreat Panel

The only FDA-cleared multi-target biothreat product developed and manufactured by a U.S. owned company The only FDA-cleared multi-target biothreat product developed and manufactured by a U.S. owned company

T2 Biosystems Receives FDA 510(k) Clearance for the T2Biothreat Panel

T2 Biosystems (NASDAQ: TTOO ) stock is the top-trending ticker on social media, and its shares are up over 30% today after the Food and Drug Administration (FDA) allowed the company to start marketing its biothreat panel in America. More About the FDA's Decision and T2's Biothreat Panel Over the weekend, the FDA disclosed that it had determined that T2's Biothreat Panel was “Substantially Equivalent” to an existing product that the agency has already approved.

Why Is T2 Biosystems (TTOO) Stock Up 30% Today?

T2 Biosystems (NASDAQ: TTOO) stock price made a strong comeback during the pre-market session as investors bought the dip. The shares surged by more than 40%, its best daily performance since August.

TTOO stock price is flying: How high can T2 Biosystems go?

Aurora Cannabis

SNDL Inc.

Today we look at some of the most active penny stocks to watch. If you're new to trading, in general, we'll first go into some of the ins and outs of trading, including a background on low-priced stocks.

Best Penny Stocks To Watch? 3 For Your List In September

Shareholders of T2 Biosystems (NASDAQ: TTOO ) stock will have to wait a bit longer for the company to hold its 2023 annual meeting of stockholders. Yesterday, the diagnostics company announced that it would reschedule the meeting to Sept.

News for T2 Biosystems Stock (TTOO)